

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Sisram Medical Ltd
復銳醫療科技有限公司*
(Incorporated in Israel with limited liability)
(Stock Code: 1696)

RENEWAL OF CONTINUING CONNECTED TRANSACTIONS

**RELATING TO THE NEW SUBLICENSE AGREEMENT AND
THE NEW PROMOTIONAL SERVICES AGREEMENTS**

**RENEWAL OF CONTINUING CONNECTED TRANSACTIONS RELATING TO THE
NEW SUBLICENSE AGREEMENT AND THE NEW PROMOTIONAL SERVICES
AGREEMENTS**

Reference is made to the announcements of the Company dated July 10, 2026 and September 28, 2026 in relation to, among others, (i) entering into the Existing Sublicense Agreement and the Existing Promotional Services Agreements; and (ii) the extension of the Existing Sublicense Agreement and the Existing Promotional Services Agreements.

As the Existing Sublicense Agreement and the Existing Promotional Services Agreements will expire on December 31, 2026 and the Group intends to continue to enter into transactions of similar nature after the expiry date, Sisram Tianjin and Fosun Wanbang (Jiangsu) entered into the New Sublicense Agreement and the New Promotional Services Agreements for a term commencing from January 1, 2027 to December 31, 2027 to continue the transactions.

LISTING RULES IMPLICATIONS

As at the date of this announcement, Fosun Wanbang (Jiangsu) is an indirect wholly-owned subsidiary of Fosun Pharma and Fosun Pharma is the controlling shareholder of the Company. Therefore, Fosun Wanbang (Jiangsu) is a connected person of the Company. Accordingly, the entering into of the New Sublicense Agreement and the New Promotional Services Agreements would constitute continuing connected transactions of the Company under Chapter 14A of the Listing Rules.

The transactions contemplated under the New Sublicense Agreement and the New Promotional Services Agreements shall be aggregated for the purpose of classification of connected transactions in accordance with Rule 14A.81 of the Listing Rules. As one or more of the applicable percentage ratio in respect of the annual caps of the transactions contemplated under the New Sublicense Agreement and the New Promotional Services Agreements on an aggregated basis are more than 5%, the transactions under the New Sublicense Agreement and the New Promotional Services Agreements are subject to the reporting, annual review and announcement requirements as well as the circular and independent shareholders' approval requirements under Chapter 14A of the Listing Rules.

FORMATION OF AN INDEPENDENT BOARD COMMITTEE AND APPOINTMENT OF INDEPENDENT FINANCIAL ADVISER

An Independent Board Committee comprising all the independent non-executive Directors has been formed to advise the Independent Shareholders as to (i) whether the New Sublicense Agreement and the New Promotional Services Agreements are entered into in the ordinary and usual course of business of the Group, (ii) whether the terms of the New Sublicense Agreement and the New Promotional Services Agreements and the proposed annual caps of the transactions contemplated thereunder are on normal commercial terms, fair and reasonable so far as the Independent Shareholders are concerned and in the interests of the Company and the Shareholders as a whole, and (iii) how to vote in respect of the relevant resolution to be proposed at the EGM.

Rainbow Capital has been appointed as the Independent Financial Adviser to advise the Independent Board Committee and the Independent Shareholders in this respect.

CIRCULAR

The Company will convene an EGM to seek approval from the Independent Shareholders in respect of the New Sublicense Agreement and the New Promotional Services Agreements and the proposed annual caps of the transactions contemplated thereunder. A circular containing, among other things, (i) the details of the New Sublicense Agreement and the New Promotional Services Agreements and the proposed annual caps of the transactions contemplated thereunder; (ii) the letter from the Independent Board Committee; (iii) the letter from the Independent Financial Adviser; (iv) the notice of EGM; and (v) other information as required under the Listing Rules is expected to be despatched to the Shareholders no later than October 21, 2026.

A. BACKGROUND

Reference is made to the announcements of the Company dated July 10, 2026 and September 28, 2026 in relation to, among others, (i) entering into the Existing Sublicense Agreement and the Existing Promotional Services Agreements; and (ii) the extension of the Existing Sublicense Agreement and the Existing Promotional Services Agreements (collectively, the “**Announcements**”). As the Existing Sublicense Agreement and the Existing Promotional Services Agreements will expire on December 31, 2026 and the Group intends to continue to enter into transactions of similar nature after the expiry date, Sisram Tianjin and Fosun Wanbang (Jiangsu) entered into the New Sublicense Agreement and the New Promotional Services Agreements for a term commencing from January 1, 2027 to December 31, 2027 to continue the transactions.

B. ENTERING INTO THE NEW SUBLICENSE AGREEMENT AND THE NEW PROMOTIONAL SERVICES AGREEMENTS

(I) New Sublicense Agreement

The principal terms of the New Sublicense Agreement are set out below:

Date	: September 28, 2026
Parties	: a) Sisram Tianjin; and b) Fosun Wanbang (Jiangsu).
Subject Matter	: Pursuant to the New Sublicense Agreement, Sisram Tianjin agreed to authorise Fosun Wanbang (Jiangsu) to handle the following aspects of the Product in the Territory, including, among others: (i) import, procurement, customs clearance, legal inspection, warehousing transportation and general distribution; (ii) commercial channel distribution; and (iii) warehousing space, operational procedures, and related systems.
Supply Region	: PRC
Term	: The New Sublicense Agreement shall take effect upon execution by the parties, commencing from January 1, 2027 and expiring on December 31, 2027, subject to approval by the Independent Shareholders at the EGM.

Royalty Fees : The royalty fees (excluding VAT) to be paid by Fosun Wanbang (Jiangsu) to Sisram Tianjin under the New Sublicense Agreement shall be determined based on the following formula:

**Revenue generated by Fosun Wanbang (Jiangsu)
from the sales of the Product in the Territory x 20%**

Such royalty fees are determined on an arm's length basis and with reference to, (i) the expected amount of revenue generated by Fosun Wanbang (Jiangsu) from the sales of the Product in the Territory; (ii) prevailing market conditions; and (iii) the cost incurred by the Group for obtaining the license of the Product.

Settlement : The royalty fees shall be settled on a monthly basis. Sisram Tianjin shall issue legally valid and compliant special VAT invoices to Fosun Wanbang (Jiangsu).

(II) New Promotional Services Agreements

The principal terms of the New Promotional Services Agreements are set out below:

Date : September 28, 2026

Parties : a) Fosun Wanbang (Jiangsu); and
b) Sisram Tianjin.

Subject Matter : Fosun Wanbang (Jiangsu) agreed to engage Sisram Tianjin to provide promotional services for the Product in the Territory, including, among others, the marketing promotion, academic publicity, formulation and implementation of marketing and commercialization policies.

Supply Region : PRC

Term : The New Promotional Services Agreements shall take effect upon execution by the parties, commencing from January 1, 2027 and expiring on December 31, 2027, subject to approval by the Independent Shareholders at the EGM.

Promotional Services Fees : The promotional services fees to be paid by Fosun Wanbang (Jiangsu) to Sisram Tianjin under the New Promotional Services Agreements shall be determined based on the following formula:

$$\text{Promotional services fees} = \text{Total Amount of Sales (excluding VAT)} - \text{Procurement Costs and Import Tax} - \text{Operating Costs} - \text{Royalty Fees} - \text{Other Expenses}$$

For the purpose of the above formula:

“**Total Amount of Sales**” means the total amount of revenue from the sale of the Product by Fosun Wanbang (Jiangsu) in the Territory (excluding VAT).

“**Procurement Costs and Import Tax**” means the (i) actual amount paid by Fosun Wanbang (Jiangsu) for the import and procurement of the Product (comprising the price of the Product only and excluding fees such as custom clearance, transportation and insurance fees); and (ii) the amount of taxes paid by Fosun Wanbang (Jiangsu) for the import of the Product (excluding VAT).

“**Operating Costs**” means the operating costs incurred by Fosun Wanbang (Jiangsu) for conducting businesses relating to the Product such as international logistics fees, domestic logistics fees and warehousing fees.

“**Royalty Fees**” means the royalty fees that shall be paid by Fosun Wanbang (Jiangsu) to Sisram Tianjin pursuant to the New Sublicense Agreement.

“**Other Expenses**” means fees arising from, including but not limited to, the registration and re-registration, pharmacovigilance, product quality insurance, test samples, legal inspection samples, returns and loss reported, near-expiry loss reported for the Product (excluding losses caused by the operations of Fosun Wanbang (Jiangsu)).

Settlement : The promotional services fees shall be settled upon completion of monthly reconciliation between parties. Sisram Tianjin shall issue legally valid and compliant special VAT invoices to Fosun Wanbang (Jiangsu).

Pursuant to the New Promotional Services Agreements, Fosun Wanbang (Jiangsu) will defer deduction of one-third of the Operating Costs for 2027. The deferred amounts, together with a 3% per annum interest subsidy thereon, will be paid by Sisram Tianjin to Fosun Wanbang (Jiangsu) in the first quarter of 2030. For completeness and as previously disclosed in the Announcements, a settlement arrangement also applies to the Operating Costs for the period from October 1, 2026 to December 31, 2026, under which two-thirds thereof are deferred. The deferred amounts, together with a 3% per annum interest subsidy thereon, will be paid by Sisram Tianjin to Fosun Wanbang (Jiangsu) in the first quarter of 2029 (collectively, the “**Settlement Arrangements**”).

C. HISTORICAL TRANSACTION AMOUNTS

There were no historical transactions between Sisram Tianjin and Fosun Wanbang (Jiangsu) in relation to the transactions contemplated under the Original Commercial Distribution Co-operation Agreement for the period from September 22, 2025 to December 31, 2025, as the Product has only passed quality testing from the National Institutes for Food and Drug Control of the PRC in early 2026 and therefore commenced its commercialization thereafter. For the period from January 1, 2026 to August 31, 2026, the aggregate transaction amount between Sisram Tianjin and Fosun Wanbang (Jiangsu) in relation to the transactions contemplated under the Existing Sublicense Agreement and the Existing Promotional Services Agreements was approximately US\$3,460,000, comprising approximately US\$2,080,000 in respect of promotional services fees and approximately US\$1,380,000 in respect of royalty fees.

As at the date of this announcement, the existing maximum transaction amounts for the year ended December 31, 2026 under the Existing Sublicense Agreement and the Existing Promotional Services Agreements had not been exceeded.

D. ANNUAL CAPS AND THE BASIS OF DETERMINATION

Set out below are the proposed annual caps in respect of the transactions contemplated under the New Sublicense Agreement and the New Promotional Services Agreements for the following periods:

	For the year from January 1 to December 31, 2027 (US\$)
The New Sublicense Agreement	6,500,000
The New Promotional Services Agreements	8,500,000
Aggregate annual caps	<u>15,000,000</u>

In respect of the New Sublicense Agreement, the annual cap was determined with reference to the following factors: (i) the estimated volume of sales of the Product by Fosun Wanbang (Jiangsu), having regard to the historical sales performance of the Product and the projected demand in the PRC market; and (ii) the prevailing market price of the Product (or same/similar types of products on the market) sold to hospitals and clinics.

In respect of the New Promotional Services Agreements, the annual cap was determined with reference to the following factors: (i) the estimated volume of sales of the Product by Fosun Wanbang (Jiangsu), having regard to the historical sales performance of the Product and the projected demand in the PRC market; (ii) the prevailing market price of the Product (or same/similar types of products on the market) sold to hospitals and clinics; and (iii) the estimated operating costs and expenses to be incurred by Fosun Wanbang (Jiangsu) during the course of sales of the Product, including costs relating to the warehousing and distribution for the Product.

E. REASONS FOR, AND BENEFITS OF, THE ADOPTION OF THE ENTERING INTO OF THE NEW SUBLICENSE AGREEMENT AND THE NEW PROMOTIONAL SERVICES AGREEMENTS

The entering into the New Sublicense Agreement and the New Promotional Services Agreements is intended to ensure continuity and stability of business and operations in respect of the Product. The parties have an established working relationship in respect of the Product, and Fosun Wanbang (Jiangsu) also purchases the Product from Sisram HK pursuant to the supply framework agreement entered into between them, as disclosed in the Company's announcement dated May 22, 2026 and the circular dated June 24, 2026. As such, both parties are familiar with the Product's characteristics, standards and service requirements, and are able to align on the relevant quality, operational and service standards in conducting the transactions contemplated under the New Sublicense Agreement and the New Promotional Services Agreements.

The Group considers that Fosun Wanbang (Jiangsu) has the resources and professional capabilities required for the transactions contemplated under the New Sublicense Agreement and the New Promotional Services Agreements. The botulinum toxin industry in the PRC is highly regulated, and Fosun Wanbang (Jiangsu) is one of a limited number of institutions possessing the requisite qualifications for the import and distribution of toxic drugs for medical use, together with nationwide distribution capability. In light of the regulatory requirements applicable to the Product, the established cooperation between the parties and Fosun Wanbang (Jiangsu)'s relevant qualifications, distribution network and operational capability, the Group believes that the entering into of the New Sublicense Agreement and the New Promotional Services Agreements would enable the Group to maintain an effective and compliant commercialization arrangement for the Product in the Territory.

The Settlement Arrangements under the New Promotional Services Agreements provided by Fosun Wanbang (Jiangsu) to the Group are on normal commercial terms and are in the interest of the Group. No security over the assets of the Group will be granted in respect of such Settlement Arrangements. The Settlement Arrangements will therefore be fully exempt from all reporting, announcement and independent shareholders' approval requirements pursuant to Rule 14A.90 of the Listing Rules.

The Company believes that the terms of the transactions under the New Sublicense Agreement and the New Promotional Services Agreements are fair and reasonable, and conducted on normal commercial terms, having taken into account: (i) the market practices, terms and pricing mechanisms adopted by other independent parties qualified to operate in this tightly regulated sector; (ii) the comparable fee arrangements observed in similar transactions; and (iii) the independent commercial negotiations carried out between the Company and Fosun Wanbang (Jiangsu). No preferential treatment has been granted to the connected person.

Accordingly, the Board (other than the Independent Non-executive Directors whose opinion will be given after receiving advice from the Independent Financial Adviser) is of the view that the terms of the New Sublicense Agreement, the New Promotional Services Agreements and the transactions contemplated thereunder are fair and reasonable, on normal commercial terms or better, in the ordinary and usual course of business of the Group and in the interests of the Company and the Shareholders as a whole.

Mr. Lior Moshe DAYAN, Mr. Jiahong LI, Mr. Yi LIU, Ms. Rongli FENG and Ms. Caroline Xiaokui JIN declared that they also hold certain positions in Fosun Pharma and/or its subsidiaries (other than the Group). According to the Israeli laws and regulations, those Directors are considered to have a personal interest in the New Sublicense Agreement and the New Promotional Services Agreements (including the transactions contemplated thereunder) and are required to abstain from voting on the resolution of the Board approving the New Sublicense Agreement and the New Promotional Services Agreements and the proposed annual caps of the transactions contemplated thereunder. However, the Israeli laws and regulations further provide that, a director may be present at the meeting of the board of directors in relation to a transaction and may participate in the voting if the majority of the directors of the

company have a personal interest in such transaction. Accordingly, such Directors were not required to abstain from voting on the resolution of the Board approving the New Sublicense Agreement and the New Promotional Services Agreements and the proposed annual caps of the transactions contemplated thereunder. None of the Directors has any material interest in New Sublicense Agreement and the New Promotional Services Agreements and the proposed annual caps of the transactions contemplated thereunder and has to abstain from voting for the reason of having a material interest in the same.

F. INFORMATION ON THE PARTIES

Information on Fosun Wanbang (Jiangsu)

Fosun Wanbang (Jiangsu) is an indirect wholly-owned subsidiary of Fosun Pharma, the controlling shareholder of the Company. It is mainly engaged in the wholesale of medical drugs.

Information on Sisram Tianjin

Sisram Tianjin is a wholly-owned subsidiary of the Company. The Company is a leading global provider of energy-based medical aesthetic treatment systems, with comprehensive in-house capability to design, develop and produce such systems, which often feature its innovative and proprietary technologies.

G. LISTING RULES IMPLICATIONS

As at the date of this announcement, Fosun Wanbang (Jiangsu) is an indirect wholly-owned subsidiary of Fosun Pharma and Fosun Pharma is the controlling shareholder of the Company. Therefore, Fosun Wanbang (Jiangsu) is a connected person of the Company. Accordingly, the entering into of the New Sublicense Agreement and the New Promotional Services Agreements would constitute continuing connected transactions of the Company under Chapter 14A of the Listing Rules.

The transactions contemplated under the New Sublicense Agreement and the New Promotional Services Agreements shall be aggregated for the purpose of classification of connected transactions in accordance with Rule 14A.81 of the Listing Rules. As one or more of the applicable percentage ratio in respect of the annual caps of the transactions contemplated under the New Sublicense Agreement and the New Promotional Services Agreements on an aggregated basis are more than 5%, the transactions under the New Sublicense Agreement and the New Promotional Services Agreements are subject to the reporting, annual review and announcement requirements as well as the circular and independent shareholders' approval requirements under Chapter 14A of the Listing Rules.

H. INTERNAL CONTROLS

The Company has a system to monitor its connected transactions and continuing connected transactions, which includes maintaining and regularly updating the list of connected persons of the Company, checking the contracting party in each transaction to confirm whether it is a connected person, monitoring the value of transactions that are identified as connected transactions against the thresholds for triggering disclosure and shareholder approval requirements under the Listing Rules and ensuring that relevant business departments are regularly updated in relation to the renewal of connected transactions. The Company will implement its internal controls measures and review the measures periodically to ensure applicable Listing Rules requirements will be complied with. Such measures include: (i) the relevant representatives of the Group and its controlling shareholders will meet more regularly to discuss any potential transactions between the Company and its controlling shareholders; (ii) the Company's auditors, Ernst & Young, will review the Group's related party transactions and connected transactions during the audit and financial reporting process, and will report and discuss with the Audit Committee of the Company specifically on these transactions accordingly; (iii) the independent non-executive Directors will perform an annual review on the continuing connected transactions under the New Sublicense Agreement and the New Promotional Services Agreements and confirm in the annual report of the Company that the transactions have been entered into in the ordinary and usual course of business of the Group, on normal commercial terms or better, and according to the agreements governing them on terms that are fair and reasonable and in the interests of the Shareholders as a whole; and (iv) the Company will provide additional training on a regular basis to the Directors and the senior management of the Company on the requirements and updates on the regulatory regime regarding connected transactions.

By implementing the above procedures and internal control measures, the Board believes that the Group has established adequate internal control measures to ensure compliance with the annual caps and that the terms under the New Sublicense Agreement and the New Promotional Services Agreements would be in line with market terms and normal commercial terms, which are fair and reasonable, and in the interests of the Company and its shareholders as a whole.

I. FORMATION OF AN INDEPENDENT BOARD COMMITTEE AND APPOINTMENT OF INDEPENDENT FINANCIAL ADVISER

An Independent Board Committee comprising all the independent non-executive Directors has been formed to advise the Independent Shareholders as to (i) whether the New Sublicense Agreement and the New Promotional Services Agreements are entered into in the ordinary and usual course of business of the Group, (ii) whether the terms of the New Sublicense Agreement and the New Promotional Services Agreements and the proposed annual caps of the transactions contemplated thereunder are on normal commercial terms, fair and reasonable so far as the Independent Shareholders are concerned and in the interests of the Company and the Shareholders as a whole, and (iii) how to vote in respect of the relevant resolution to be proposed at the EGM.

Rainbow Capital has been appointed as the Independent Financial Adviser to advise the Independent Board Committee and the Independent Shareholders in this respect.

J. CIRCULAR

The Company will convene an EGM to seek approval from the Independent Shareholders in respect of the New Sublicense Agreement and the New Promotional Services Agreements and the proposed annual caps of the transactions contemplated thereunder. A circular containing, among other things, (i) the details of the New Sublicense Agreement and the New Promotional Services Agreements and the proposed annual caps of the transactions contemplated thereunder; (ii) the letter from the Independent Board Committee; (iii) the letter from the Independent Financial Adviser; (iv) the notice of EGM; and (v) other information as required under the Listing Rules is expected to be despatched to the Shareholders no later than October 21, 2026.

K. EGM

The EGM will be convened for the Independent Shareholders to consider and, if thought fit, approve the New Sublicense Agreement and the New Promotional Services Agreements and the proposed annual caps of the transactions contemplated thereunder.

DEFINITIONS

In this announcement, unless the context otherwise requires, the following expressions have the following meanings:

“Board”	the board of Directors
“Company”	Sisram Medical Ltd, a company incorporated in Israel with limited liability, the shares of which are listed on the Main Board of the Stock Exchange (Stock Code: 1696)
“connected person”	has the meaning ascribed to it under the Listing Rules
“controlling shareholder”	has the meaning ascribed to it under the Listing Rules
“Directors”	the directors of the Company
“EGM”	the extraordinary general meeting of the Company to be convened for the Independent Shareholders to consider and, if thought fit, approve the New Sublicense Agreement and the New Promotional Services Agreements and the proposed annual caps of the transactions contemplated thereunder
“Existing Promotional Services Agreements”	the promotional services agreement and its supplemental agreement entered into between Sisram Tianjin and Fosun Wanbang (Jiangsu) dated July 10, 2026 and as extended to December 31, 2026

“Existing Sublicense Agreement”	the sublicense agreement entered into between Sisram Tianjin and Fosun Wanbang (Jiangsu) dated July 10, 2026 and as extended to December 31, 2026
“Fosun Pharma”	Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (上海復星醫藥(集團)股份有限公司), a joint stock company established in the PRC with limited liability. The H shares and A shares of Fosun Pharma are listed and traded on the Main Board of the Stock Exchange (Stock Code: 2196) and Shanghai Stock Exchange (Stock Code: 600196), respectively
“Fosun Wanbang (Jiangsu)”	Fosun Wanbang (Jiangsu) Health Development Co., Ltd* (復星萬邦(江蘇)健康發展有限公司), a company established in the PRC with limited liability and a subsidiary of Fosun Pharma
“FPI”	Fosun Pharma Industrial Pte. Ltd., a company established in Singapore with limited liability, a subsidiary of Fosun Pharma and a Shareholder of the Company
“Group”	the Company and its subsidiaries
“Hong Kong”	The Hong Kong Special Administrative Region of the PRC
“Independent Board Committee”	the independent committee of the Board comprising all the independent non-executive Directors
“Independent Financial Adviser” or “Rainbow Capital”	Rainbow Capital (HK) Limited, a licensed corporation to conduct Type 1 (dealing in securities) and Type 6 (advising on corporate finance) regulated activities under the SFO and the independent financial adviser appointed by the Company to advise the Independent Board Committee and the Independent Shareholders in relation to the entering into of the New Sublicense Agreement and the New Promotional Services Agreements, the transactions contemplated thereunder and the proposed annual caps for the transactions contemplated thereunder
“Independent Shareholders”	Shareholders other than FPI
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange, as amended or supplemented from time to time
“New Promotional Services Agreements”	the promotional services agreement and its supplemental agreement entered into between Fosun Wanbang (Jiangsu) and Sisram Tianjin dated September 28, 2026
“New Sublicense Agreement”	the sublicense agreement entered into between Sisram Tianjin and Fosun Wanbang (Jiangsu) dated September 28, 2026

“Original Commercial Distribution Co-operation Agreement”	the commercial distribution co-operation agreement between Sisram Tianjin and Fosun Wanbang (Jiangsu) dated 22 September 2025 in relation to, among other things, the distribution of the Product, for the term from 22 September 2025 to 21 September 2026, which was superseded and replaced by the Existing Promotional Services Agreements and the Existing Sublicense Agreement
“PRC”	the People’s Republic of China, which for the purpose of this announcement only, excludes Hong Kong, the Macau Special Administrative Region of the PRC and Taiwan
“Product”	Botulinum toxin type A for injection (DaxibotulinumtoxinA-lanm, with the trademark of 达希斐® in the PRC and the English trademark of DAXXIFY®, project code RT002)
“Shareholder(s)”	the holder(s) of Shares
“Shares”	ordinary shares in the share capital of the Company
“Sisram HK”	Sisram Medical HK Limited, a company incorporated in Hong Kong with limited liability and a wholly-owned subsidiary of the Company
“Sisram Tianjin”	Sisram Medical (Tianjin) Limited* (復銳醫療科技(天津)有限公司), a company established in the PRC with limited liability and a wholly-owned subsidiary of the Company
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Territory”	Mainland China (excluding the Hong Kong Special Administrative Region of the PRC, the Macau Special Administrative Region of the PRC and Taiwan for the purpose of the New Sublicense Agreement, the New Promotional Services Agreements and the Original Commercial Distribution Co-operation Agreement)
“US\$”	United States dollars, the lawful currency of the United States of America
“%”	per cent.

* For identification purposes only.

On behalf of the Board
Sisram Medical Ltd
復銳醫療科技有限公司*
Lior Moshe DAYAN
Chairman

Hong Kong, September 28, 2026

As at the date of this notice, the board of directors of the Company comprises Mr. Lior Moshe DAYAN and Mr. Jiahong LI as executive directors; Mr. Yi LIU, Ms. Rongli FENG and Ms. Caroline Xiaokui JIN as non-executive directors; Mr. Heung Sang Addy FONG, Mr. Chi Fung Leo CHAN, Ms. Jenny CHEN and Mr. Kai Yu Kenneth LIU as independent non-executive directors.